HCC cells treated with multiple anti-tumor drugs can release more exosomal linc-VLDLR, and a study has shown that exosomal linc-VLDLR is a new medium for the development of resistance in HCC cells [122]. This evidence concerns the gene VLDLR-AS1 and neoplasm.